Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Aeon Biopharma Inc AEON

Healthcare Biotechnology
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of... see more

Recent & Breaking News (NYSEAM:AEON)

AEON Biopharma Appoints John Bencich as Chief Financial Officer

GlobeNewswire 7 days ago

AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting

GlobeNewswire 11 days ago

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

GlobeNewswire January 21, 2026

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

GlobeNewswire December 19, 2025

AEON Biopharma Announces Execution of Exchange Agreement with Daewoong

GlobeNewswire December 15, 2025

AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling

GlobeNewswire November 20, 2025

AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth

GlobeNewswire November 14, 2025

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

GlobeNewswire May 23, 2025

AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025

GlobeNewswire May 19, 2025

AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire May 14, 2025

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

GlobeNewswire April 25, 2025

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

GlobeNewswire April 21, 2025

AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer

GlobeNewswire April 21, 2025

AEON Biopharma Announces CEO Transition

GlobeNewswire March 27, 2025

AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire March 24, 2025

AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference

GlobeNewswire March 4, 2025

AEON Biopharma, Inc. Announces Reverse Stock Split

GlobeNewswire February 24, 2025

AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

GlobeNewswire February 7, 2025

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

GlobeNewswire January 7, 2025

AEON Biopharma, Inc. Announces Pricing of Approximately $20.0 Million Underwritten Public Offering

GlobeNewswire January 6, 2025

Podcasts